In a landmark trial of 17,604 overweight and obese patients with heart disease, weekly injections of semaglutide—the active ingredient in Wegovy and its twin Ozempic—for an average of 33 months reduced the risk of heart attack, stroke, and death from cardiovascular causes by 20 percent compared with a placebo group. The results were published in the New England Journal of Medicine and presented at the American Heart Association’s annual meeting Saturday morning.
“Treating obesity clearly improves health outcomes,” said Ania Jastreboff, an endocrinologist and obesity expert at the Yale School of Medicine, at a November 10 news conference with reporters ahead of the meeting in Philadelphia. Jastreboff, who wasn’t involved in the study, said the trial could be a “turning point” for treating cardiovascular disease. In a previous trial, semaglutide was shown to reduce cardiovascular risk in patients with diabetes who were overweight or obese. But in the current trial, none of the participants had a history of diabete
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: TIMEHealth - 🏆 121. / 63 Read more »
Source: TODAYshow - 🏆 389. / 55 Read more »